The 12-ICML will bring 3’000 physicians to Lugano from all over the world: haematologists, clinical oncologists, radio-oncologists, paediatricians, pathologists and leading researchers involved in the study and treatment of lymphoid neoplasms.
Application for European CME accreditation (ECMEC) will be made to the Federation of European Cancer Societies (FECS). European credits are recognised by the American Medical Association (AMA).
12- ICML program will be part of the Certificate of Competence in Lymphoma, a 1-year ECTS program developed by ESO and academically recognized by Ulm University. The aim of the Certificate of Competence is to provide a curriculum of studies to advance knowledge and science in the management of lymphoma patients. Further information can be obtained visiting
http://www.eso.net/pagine-interne/ccl-introduction.html
As recognition of his lifetime achievements, the members of the Organizing Committee and the Advisory Board have asked Prof Franco Cavalli to hold the Kaplan Lecture. The scientific program will therefore open with the lecture: “The evolution of lymphoma understanding and treatment from 1-ICML (1981) to 12-ICML (2013)”.
The Kaplan Lecture has previously been conferred to:
|
Based on the abstracts received and accepted for oral presentation, general sessions 1-13 will be devoted to either specific subtypes of lymphoid neoplasia (e.g. mantle cell lymphomas, follicular lymphomas, T-cell lymphomas, etc), or to the presentation of laboratory and clinical research data grouped around a biologic topic (for example, microenvironment, signalling pathway, surface antigens, immunology). The latter sessions will be introduced by an expert summarizing the topic.
«Focus on...» sessions highlight abstracts of scientific value but not selected for oral presentation during general sessions. These sessions will be run in parallel and each will be focused on a particular topic. The one-hour sessions will consist of six presentations of 10 minutes each, including discussion.
Clinical discussion sessions are for the clinicians who do not to attend the mainly laboratory-oriented sessions held on Thursday and Friday morning. Each session will have presenters of outstanding centers addressing cases which are not trivial nor very rare, but rather situations which are relatively commonly encountered but the solutions of which remains controversial. Every session will also have a chairman and two discussants.
12-ICML will present many novelties in its program. Here, the most relevant ones:
- Plenary session: this will be a new session, which will take place just after the Opening of ICML and the Kaplan Lecture. During the Plenary session the three-four best abstracts will be presented orally and their relevance discussed by a worldwide known expert.
- Educational symposia: besides the traditional “Meet the Professor” sessions, for the first time, the 12-ICML will also include two educational symposia with different speakers who will dissect specific topics.
- Special sessions devoted to radiotherapy, organized in collaboration with ILROG (International Lymphoma Radiation Oncology Group): a Satellite Workshop on “Modern Radiotherapy for Lymphomas – Concepts and Treatment guidelines” will take place on Tuesday June 18, 15:30 – 18:00, open to all 12-ICML attendees. Furthermore, a Special Session on “Contouring in Modern Lymphoma Radiotherapy Planning” will be held on Saturday June 22, 08:00 – 10:30, for max. 30 lymphoma radiation oncologists.
- Extra space for pediatric oncology besides the usual session (session 7), we will have a “Meet the Professor” session and a Clinical case discussion devoted to pediatric oncology. Should there be a sufficient amount of abstracts, which will be deemed to be interesting for the overall audience of ICML, a “Focus on pediatric lymphomas” session will be added to the program. Of course, pediatric abstracts will be eligible also for the Plenary session.
- Poster presentation: there will be a presentation of the best posters during the 2 lunch breaks of Thursday (June 20) and Friday (June 21).
- Session on Ongoing trials: this new session will be also structured based on the received abstracts, which will be dealing with ongoing trials. Preconditions for being selected for presentation at this are that the trials have already started, that there is sufficient time left for accrual and that they still allow for new participating investigators to join. The session should not be regarded as an advertisement for new drugs or for trials which are close to completion.
Educational symposia (parallel sessions – Wednesday, June 19 – 09:00-10:30)
- Multiple Myeloma
Chair: S.Vincent Rajkumar, Rochester, MN (USA)
Speakers: P. Leif Bergsagel, Scottsdale, AZ (USA) and Philippe Moreau, Nantes (France) - Diffuse large B-cell lymphoma subtypes
Chair: Peter W.M. Johnson, Southampton (UK)
Speakers: Miguel A. Piris, Madrid (Spain) and Louis M. Staudt, Bethesda, MD (USA)
Controversies
- Controversy I (Wednesday, June 19 – 11:00-12:00)
Does radiotherapy still have a role in primary CNS lymphoma? - Controversy II (Friday, June 21 – 15:15-16:15)
Which is the best treatment for high-risk DLBCL in young patients: R-ACVBP vs R-CHOP
Key Note Lectures
- Kaplan Lecture(Wednesday, June 19 – 13:00-14:00)
The evolution of lymphoma understanding and treatment from 1-ICML (1981) to 12-ICML (2013) Franco Cavalli, Bellinzona (Switzerland) - Rappaport Lecture (Thursday, June 20 - 13:00-14:00)
Early lymphomas
Elaine Jaffe, Bethesda, MD (USA) - Ultmann Lecture (Friday, June 21 - 13:00-14:00)
Hodgkin Lymphoma – The Great Teacher
Joseph Connors, Vancouver, B.C. (Canada) - 12-ICML Highlights (Saturday, June 22 – 11:00-11:30)
“Take home messages”
James O. Armitage, Omaha, NE (USA)
PROVISIONAL LIST OF MEET THE PROFESSOR SESSIONS:
- CNS prophylaxis in aggressive lymphomas: for whom and how.
Umberto Vitolo, Turin (Italy) - Extranodal lymphomas in rare localisations (bone, breast and others).
John F. Seymour, Melbourne (Australia) - CLL: new genetic markers as prognostic factors.
Davide Rossi, Novara (Italy) - New markers in T-cell lymphoma: more entities or more confusion?
Philippe Gaulard, Créteil (France) - The rational for combining targeted and biological anti-lymphoma drugs.
Anas Younes, Houston, TX (USA) - Malignant lymphoma as a consequence of clonal evolution.
Masao Seto, Nagoya (Japan) - Management of nodular lymphocyte predominant Hodgkin’s Lymphoma
Andreas Engert, Cologne (Germany) - Hodgkin Lymphoma in the Elderly.
Andrew M. Evens, Worcester, MA (USA) - How to treat children and adolescents with relapsed Non-Hodgkin Lymphoma?
Alfred Reiter, Giessen (Germany) - Waldenström Macroglobulinemia: just another indolent lymphoma?
Steven P.Treon, Boston, MA (USA)
NB: A Satellite Workshop on: “Canine Lymphoma: State of the Art and Comparative Aspects with Human Disease” will take place on Saturday June 22, 13:15-18:00, and will be open to all 12-ICML attendees. The worshop will deal with comparative aspects related to pathogenesis, diagnosis and classification, and therapy (http://eu-can-lymph.net).
SESSIONE INFERMIERISTICA (venerdì, 21 giugno 2013 - 11:00-17:40)
Auditorium, Università della Svizzera Italiana
Per la prima volta quest’anno si è pensato di inserire una sessione infermieristica nel più importante
Forum Internazionale sui Linfomi.
L’obiettivo è di stimolare il dibattito anche tra il personale Infermieristico e creare un primo importante momento di incontro.
Per questo primo evento la lingua ufficiale sarà l’italiano.